Attention & Memory Impairments in Menopausal Women

PHASE4CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

May 31, 2011

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions
Symptomatic MenopauseCognitive Impairments
Interventions
DRUG

Lisdexamfetamine

In a counterbalanced fashion, participants would receive titrated doses of LDX 20 to 60 mg/d for 4 weeks followed by a 2-week washout and then crossed over to the placebo tablets for another 4 weeks. All women will start with LDX 20 mg/d and then be titrated to 40 mg/d after 1 week and 60 mg/d after 2 weeks (as tolerated).

DRUG

Placebo

In a counterbalanced fashion, participants would receive placebo tablets for 4 weeks followed by a 2 week washout, then will receive titrated doses of LDX 20 to 60 mg/d for 4 weeks.

Trial Locations (1)

19104

Penn Center for Women's Behavioral Wellness, Philadelphia

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Shire

INDUSTRY

lead

University of Pennsylvania

OTHER

NCT01324024 - Attention & Memory Impairments in Menopausal Women | Biotech Hunter | Biotech Hunter